| Schedule of segment reporting information, by segment |
| | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | 2026 | | 2025 | | 2026 | | 2025 | Revenue | $ | — | | $ | 2,733,000 | | $ | — | | $ | 2,790,000 | Less: | | | | | | | | | | | | Research and development expenses: | | | | | | | | | | | | Preclinical & clinical development | | (85,000) | | | 1,897,475 | | | 2,528,000 | | | 2,524,475 | Personnel related | | 472,000 | | | 425,000 | | | 861,000 | | | 890,000 | Other research and development (a) | | 714,000 | | | (31,475) | | | 2,624,000 | | | 1,382,525 | Total research and development expenses | | 1,101,000 | | | 2,291,000 | | | 6,013,000 | | | 4,797,000 | General and administrative expenses: | | | | | | | | | | | | Professional & consulting fees | | 1,512,000 | | | 634,000 | | | 2,297,000 | | | 1,826,000 | Personnel related | | 510,000 | | | 512,000 | | | 1,176,000 | | | 1,416,000 | Other general and administrative (b) | | 1,457,000 | | | 545,000 | | | 2,040,000 | | | 1,203,000 | Total general and administrative | | 3,479,000 | | | 1,691,000 | | | 5,513,000 | | | 4,445,000 | Other operating income (c) | | (1,405,000) | | | — | | | (1,405,000) | | | — | Change in fair value of warrant liability | | (215,000) | | | (146,000) | | | (56,000) | | | (26,659,000) | Other loss (income), net (d) | | 94,000 | | | (188,000) | | | 96,000 | | | (368,000) | Net (loss) income | $ | (3,054,000) | | $ | (915,000) | | $ | (10,161,000) | | $ | 20,575,000 | | | | | | | | | | | | |
| (a) | Other research and development expenses include stock-based compensation, manufacturing, formulation, development, and consulting fees. |
| (b) | Other general and administrative expenses include stock-based compensation, public company costs, and insurance. |
| (c) | Other operating income consists of the removal of a legacy accrued research and development obligation, which was initially recognized in a prior reporting period. During the second quarter of 2026, the Company concluded that the accrued liability was no longer probable of settlement and that no future cash outflows related to the obligation were expected. Because the amount was originally recorded as research and development expense, its removal is presented within operating expenses rather than as non-operating income. |
| (d) | Other income, net included interest income. |
|